- Multi Drug Resistant Enterococci
- Multi Drug Resistant Staphylococci
- Gram Negatives
- Others
Multi Drug Resistant Antibiotics Market size was valued at USD 9.20 billion in 2022 and is poised to grow at a CAGR of 7.2% from 2023-2029. Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the antibiotic resistance market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period. Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria. In August 2017, U.S. FDA approved The Medicines Company abomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria. In May 2014, U.S. FDA approved Durata Therapeutic (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.
The multi drug resistant antibiotics market size was valued at USD 9.20 billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The multi drug resistant antibiotics market key players are Achaogen Inc. Acetlion Pharmaceuticals Sanofi S.A Johnson & Johnson Services Pfizer Inc. Otsuka Pharmaceutical
1. Executive Summary |
2. Global Multi Drug Resistant Antibiotics Market Introduction |
2.1.Global Multi Drug Resistant Antibiotics Market - Taxonomy |
2.2.Global Multi Drug Resistant Antibiotics Market - Definitions |
2.2.1.Type of Bacteria |
2.2.2.Disease |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Multi Drug Resistant Antibiotics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Multi Drug Resistant Antibiotics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Multi Drug Resistant Antibiotics Market By Type of Bacteria, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Multi Drug Resistant Enterococci |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Multi Drug Resistant Staphylococci |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Gram Negatives |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Multi Drug Resistant Antibiotics Market By Disease, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Drug Resistant Tuberculosis |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Others |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Multi Drug Resistant Antibiotics Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Multi Drug Resistant Antibiotics Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Multi Drug Resistant Antibiotics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Type of Bacteria Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Multi Drug Resistant Enterococci |
9.1.2.Multi Drug Resistant Staphylococci |
9.1.3.Gram Negatives |
9.1.4.Others |
9.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Drug Resistant Tuberculosis |
9.2.2.Others |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Others |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Multi Drug Resistant Antibiotics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Type of Bacteria Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Multi Drug Resistant Enterococci |
10.1.2.Multi Drug Resistant Staphylococci |
10.1.3.Gram Negatives |
10.1.4.Others |
10.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Drug Resistant Tuberculosis |
10.2.2.Others |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Others |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11. Asia Pacific (APAC) Multi Drug Resistant Antibiotics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Type of Bacteria Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Multi Drug Resistant Enterococci |
11.1.2.Multi Drug Resistant Staphylococci |
11.1.3.Gram Negatives |
11.1.4.Others |
11.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Drug Resistant Tuberculosis |
11.2.2.Others |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Others |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Multi Drug Resistant Antibiotics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Type of Bacteria Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Multi Drug Resistant Enterococci |
12.1.2.Multi Drug Resistant Staphylococci |
12.1.3.Gram Negatives |
12.1.4.Others |
12.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Drug Resistant Tuberculosis |
12.2.2.Others |
12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Others |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Multi Drug Resistant Antibiotics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Type of Bacteria Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Multi Drug Resistant Enterococci |
13.1.2.Multi Drug Resistant Staphylococci |
13.1.3.Gram Negatives |
13.1.4.Others |
13.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Drug Resistant Tuberculosis |
13.2.2.Others |
13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Others |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Achaogen Inc. |
14.2.2.Acetlion Pharmaceuticals |
14.2.3.Sanofi S.A |
14.2.4.Johnson & Johnson Services |
14.2.5.Pfizer Inc. |
14.2.6.Otsuka Pharmaceutical |
14.2.7.Eli Lilly and Company |
15. Research Methodology |
16. Appendix and Abbreviations |